Molecular Partners AG (MLLCF)
USD 4.22
(0.24%)
USD 4.22
(0.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -61.98 Million CHF | -152.59% |
| 2022 | 117.85 Million CHF | 284.77% |
| 2021 | -63.78 Million CHF | -1.63% |
| 2020 | -62.76 Million CHF | -72.96% |
| 2019 | -36.28 Million CHF | 2.02% |
| 2018 | -37.03 Million CHF | -45.64% |
| 2017 | -25.43 Million CHF | -36.63% |
| 2016 | -18.61 Million CHF | -12406.13% |
| 2015 | -148.82 Thousand CHF | 93.48% |
| 2014 | -2.28 Million CHF | -131.96% |
| 2013 | 7.14 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -11.32 Million CHF | 42.75% |
| 2024 Q2 | -15.08 Million CHF | -33.17% |
| 2023 Q2 | -15.98 Million CHF | -8.18% |
| 2023 Q3 | -11.43 Million CHF | 28.45% |
| 2023 FY | -61.98 Million CHF | -152.59% |
| 2023 Q1 | -14.77 Million CHF | 15.22% |
| 2023 Q4 | -19.78 Million CHF | -72.92% |
| 2022 Q1 | 153.12 Million CHF | 955.03% |
| 2022 Q3 | -13.32 Million CHF | -194.6% |
| 2022 FY | 117.85 Million CHF | 284.77% |
| 2022 Q4 | -17.43 Million CHF | -30.84% |
| 2022 Q2 | -4.52 Million CHF | -102.95% |
| 2021 Q2 | -17.01 Million CHF | -2.77% |
| 2021 FY | -63.78 Million CHF | -1.63% |
| 2021 Q3 | -12.3 Million CHF | 27.65% |
| 2021 Q4 | -17.9 Million CHF | -45.5% |
| 2021 Q1 | -16.55 Million CHF | 23.24% |
| 2020 FY | -62.76 Million CHF | -72.96% |
| 2020 Q1 | -13.34 Million CHF | -13.36% |
| 2020 Q2 | -11.4 Million CHF | 14.55% |
| 2020 Q4 | -21.56 Million CHF | -31.11% |
| 2020 Q3 | -16.44 Million CHF | -44.25% |
| 2019 Q1 | -6.37 Million CHF | 49.66% |
| 2019 Q3 | -11.77 Million CHF | -84.75% |
| 2019 Q2 | -6.37 Million CHF | 0.0% |
| 2019 FY | -36.28 Million CHF | 2.02% |
| 2019 Q4 | -11.77 Million CHF | 0.0% |
| 2018 Q3 | -12.65 Million CHF | -116.01% |
| 2018 Q1 | -5.86 Million CHF | -93.62% |
| 2018 Q2 | -5.86 Million CHF | 0.0% |
| 2018 FY | -37.03 Million CHF | -45.64% |
| 2018 Q4 | -12.65 Million CHF | 0.0% |
| 2017 Q1 | -7.6 Million CHF | -99.37% |
| 2017 Q4 | -3.02 Million CHF | 0.0% |
| 2017 Q3 | -3.02 Million CHF | 74.3% |
| 2017 Q2 | -11.77 Million CHF | -54.96% |
| 2017 FY | -25.43 Million CHF | -36.63% |
| 2016 Q1 | -4.2 Million CHF | -410.88% |
| 2016 Q2 | -5.53 Million CHF | -31.71% |
| 2016 Q4 | -3.81 Million CHF | 25.25% |
| 2016 Q3 | -5.1 Million CHF | 7.81% |
| 2016 FY | -18.61 Million CHF | -12406.13% |
| 2015 FY | -148.82 Thousand CHF | 93.48% |
| 2015 Q4 | 1.35 Million CHF | -75.44% |
| 2015 Q3 | 5.5 Million CHF | 218.19% |
| 2015 Q2 | -4.65 Million CHF | -93.9% |
| 2015 Q1 | -2.4 Million CHF | 50.85% |
| 2014 Q2 | 758.87 Thousand CHF | -0.0% |
| 2014 Q1 | 758.87 Thousand CHF | 0.0% |
| 2014 FY | -2.28 Million CHF | -131.96% |
| 2014 Q4 | -4.88 Million CHF | -543.89% |
| 2014 Q3 | 1.1 Million CHF | 44.95% |
| 2013 FY | 7.14 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ContraFect Corporation | -65.15 Million USD | 4.864% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 17.314% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -842.563% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -22571.378% |
| SQZ Biotechnologies Company | -79.46 Million USD | 21.997% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -2043.0% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 216.997% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 195.165% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -3304.727% |
| Marizyme, Inc. | -65.34 Million USD | 5.146% |
| Genus plc | 7.9 Million USD | 884.608% |
| Pharming Group N.V. | -10.54 Million USD | -487.637% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -2756.65% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -1570.622% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -600.859% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -3488.169% |
| IMV Inc. | -36.48 Million USD | -69.886% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -669.063% |
| ONE Bio Corp. | 8.67 Million USD | 814.38% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -19.91% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -9701.283% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -2503.418% |
| Biomind Labs Inc. | -1.21 Million USD | -5004.425% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -3.782% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -684.301% |
| Skye Bioscience, Inc. | -37.64 Million USD | -64.655% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -3079.891% |
| Mesoblast Limited | -87.95 Million USD | 29.528% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -413788.889% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -787.662% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -290.538% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -965.52% |
| GB Sciences, Inc. | -1.36 Million USD | -4452.034% |
| MultiCell Technologies, Inc. | -380.07 USD | -16308474.736% |
| Alpha Cognition Inc. | -13.77 Million USD | -350.054% |
| HST Global, Inc. | -146.21 Thousand USD | -42293.817% |
| CSL Limited | 2.64 Billion USD | 102.346% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Agentix Corp. | -1.37 Million USD | -4410.515% |
| Halberd Corporation | -79.67 Thousand USD | -77695.07% |
| Enzolytics Inc. | -2.17 Million USD | -2747.441% |
| Resverlogix Corp. | -3.61 Million USD | -1617.008% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1854.446% |
| argenx SE | -295.05 Million USD | 78.992% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 63348.98% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -1560.434% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1948.289% |
| Bioxytran, Inc. | -4.28 Million USD | -1348.224% |
| Zenith Capital Corp. | -10.59 Million USD | -484.975% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -1395.054% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -102453.565% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2991.294% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -95.47 Million USD | 35.08% |
| Kadimastem Ltd | -3.3 Million USD | -1774.102% |
| Helix BioMedix, Inc. | -1.05 Million USD | -5769.38% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1898.344% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -1523.043% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -469.092% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1168.588% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -1554.487% |
| EV Biologics, Inc. | -1.26 Million USD | -4791.669% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -13943.578% |
| Q BioMed Inc. | -2.05 Million USD | -2920.526% |
| LadRx Corporation | 400.44 Thousand USD | 15578.857% |
| Cell Source, Inc. | -5.32 Million USD | -1064.847% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -14818.684% |
| Regen BioPharma, Inc. | 1.02 Million USD | 6156.035% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 0.982% |
| Itoco Inc. | -1.86 Million USD | -3216.435% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -1295.239% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -3432.313% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 995.128% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -3613.841% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -1460.134% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | -866.439% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -266589.614% |
| NovAccess Global Inc. | -4.76 Million USD | -1199.676% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -78327.998% |
| BioStem Technologies, Inc. | -8.48 Million USD | -630.686% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -27070.83% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4541.498% |
| Qrons Inc. | -789.34 Thousand USD | -7752.567% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -6483.334% |
| SYBLEU INC | -180.3 Thousand USD | -34277.496% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -2869.035% |
| Rebus Holdings, Inc. | -1.02 Million USD | -5976.863% |
| Regen BioPharma, Inc. | 1.02 Million USD | 6156.035% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -3743.404% |
| Affymax, Inc. | -14.42 Million USD | -329.728% |
| Mobile Lads Corp. | -2.26 Million USD | -2638.666% |
| International Stem Cell Corporation | -131 Thousand USD | -47216.031% |
| CytoDyn Inc. | -49.84 Million USD | -24.363% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -114109.906% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -2349.721% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -28.94% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2832.072% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -7837.64% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1856.566% |
| Neutra Corp. | -233.46 Thousand USD | -26449.59% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -205.475% |
| PureTech Health plc | -65.69 Million USD | 5.652% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -191.463% |
| IXICO plc | -1.17 Million USD | -5161.8% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -524.398% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -8.5% |
| CSL Limited | 2.64 Billion USD | 102.346% |
| Cellectis S.A. | -103.17 Million USD | 39.923% |